January 1, 2014

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption. (Funded by Amgen and UCB Pharma; ClinicalTrials.gov number, NCT00896532.).

Preguntar a la IA

Me gusta

Guardar

Cite This Study

McClung et al. (Wed,) studied this question.

synapsesocial.com/papers/69dbf1505b363cdf1c8363e1 https://doi.org/https://doi.org/10.1056/nejmoa1305224

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody2010 · 783 citations
2Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)2001 · 1,149 citations
3A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation1999 · 15,137 citations
4Osteoporosis Prevention, Diagnosis, and Therapy2001 · 5,500 citations
5Patients with sclerosteosis and disease carriers: Human models of the effect of sclerostin on bone turnover2011 · 133 citations

Preguntar a la IA

Me gusta

Guardar